肿瘤患者化疗后粒细胞集落刺激因子的应用情况  

Application of Granulocyte Colony-Stimulating Factor in Patients with Tumor After Chemotherapy

作　　者：李满 冯瑞红 邢通 李洪盟 张小轲 郭峰[1] LI Man;FENG Rui-hong;XING Tong;LI Hong-meng;ZHANG Xiao-ke;GUO Feng(Department of Pharmacy,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China;Department of Surgery,No.988 Hospital of the Joint Logistic Support Force of PLA,Zhengzhou 450000,China;Luoyang Outpatient Department of 63650 Army Hospital of PLA,Luoyang 471000,China)

机构地区：[1]郑州大学第一附属医院药学部,河南郑州450000 [2]中国人民解放军联勤保障部队第九八八医院外科,河南郑州450000 [3]中国人民解放军63650部队医院洛阳门诊部,河南洛阳471000

出　　处：《河南医学研究》2020年第34期6364-6367,共4页Henan Medical Research

摘　　要：目的探讨肿瘤患者化疗后粒细胞集落刺激因子(G-CSF)的应用情况。方法采用回顾性分析的方法,通过郑州大学第一附属医院HIS系统抽取2020年3—5月接受化疗并使用人工合成的重组人粒细胞集落刺激因子(rhG-CSF)和聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)的759例肿瘤患者的病历。统计患者的一般资料、G-CSF的用药过程、中性粒细胞绝对计数(ANC)监测情况、化疗方案等。结果759例肿瘤患者包括男341例,女418例,年龄7~83岁,平均(53.51±12.98)岁。化疗后rhG-CSF的单日剂量为150~600μg,用药时间1~12 d;PEG-rhG-CSF的单日剂量为3~6 mg,均为单次皮下注射。合理病历512例(67.46%),不合理病历247例(32.54%)。不合理情况主要为用药后未按照要求监测ANC水平(34.41%)、用药指征不适宜(29.96%)、给药疗程不适宜(18.62%)、给药时机不适宜(14.98%)等。结论G-CSF在肿瘤患者化疗后的使用存在不合理现象,需要加强对该药的应用管理。Objective To investigate the application of granulocyte colony-stimulating factor(G-CSF)in patients with tumor after chemotherapy.Methods The medical records of 759 patients with tumor who received chemotherapy and used synthetic recombinant human granulocyte colony-stimulating factor(rhG-CSF)and pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)from March to May 2020 were collected by HIS system of the First Affiliated Hospital of Zhengzhou University.The general information of the patients,the course of G-CSF administration,the monitoring of absolute neutrophil count(ANC)and chemotherapy scheme were statistically analyzed.Results Among the 759 patients with tumor,341 cases were male and 418 cases were female,with an average age of(53.51±12.98)years old,ranging from 7 to 83 years old.After chemotherapy,the daily dose of rhG-CSF was 150 to 600μg for 1 to 12 days.PEG-rhG-CSF was injected subcutaneously in a single dose of 3 to 6 mg every day.There were 512 cases(67.46%)with reasonable medical records and 247 cases(32.54%)with unreasonable medical records.The main reasons for unreasonable medical records were failure to monitor the level of ANC as required after administration(34.41%),improper medication indications(29.96%),unreasonable course of medication(18.62%),and unreasonable timing of administration(14.98%).Conclusion The use of G-CSF in patients with tumor after chemotherapy is still not standardized,so it is necessary to strengthen the application management of G-CSF.

关 键 词：化学疗法 粒细胞集落刺激因子 合理用药 

分 类 号：R973.4[医药卫生—药品]